Anthem Biosciences Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹540 - ₹570
- Lot size
- 26 shares
- Issue amount
- ₹3,395 cr
- Total subscription
- 63.89×
- Opens
- 14 Jul 2025
- Closes
- 16 Jul 2025
- Allotment
- 17 Jul 2025
- Listing
- 21 Jul 2025
Offer at a glance
Issue overview
- Issue size
- 5,95,61,404 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹14,040
- Fresh issue
- ₹0 cr
- Offer for sale
- ₹3,395 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹0
- Issue type
- Bookbuilding IPO
- Shares before issue
- 55,90,77,100
- Shares after issue
- 0
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 26 | ₹14,820 |
| sHNI | 14 | 364 | ₹2,07,480 |
| bHNI | 68 | 1,768 | ₹10,07,760 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 7,99,840 | 47,63,378 |
| HNIs(10L +) | 16,323 | 8,43,183 |
| HNIs (2-10L) | 8,162 | 2,51,514 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 677.35 | 1,30,592.47 |
| RETAIL | 1,185.36 | 7,059.33 |
| NIB | 508.01 | 22,712.77 |
| HNIs 2+ | 169.34 | 5,218.41 |
| HNIs 10+ | 338.68 | 17,494.36 |
| EMPLOYEES | 9.04 | 63.31 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 8.04 | 6.48 | 6.75 |
| ROE | 20.82 | 20.04 | 24.89 |
| ROCE | 26.88 | 25.71 | 31.69 |
| RONW | 20.82 | 20.03 | 24.93 |
| PRE IPO(PE) | 0 | 0 | 0 |
| POST IPO(PE) | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Founded in 2006, Anthem Biosciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides comprehensive services throughout the drug development process—from discovery to manufacturing. The company specializes in producing fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, vitamin analogues, and biosimilars. It supports the full journey of commercial molecules, right from initial research to market launch. By September 30, 2024, Anthem had built a global presence, serving more than 425 clients in over 44 countries, including key markets like the U.S., Europe, and Japan. Its clientele ranges from small biotech startups to major pharmaceutical companies. Anthem is actively engaged in research and development, with 196 projects underway at different stages, including discovery, early and late development phases, and commercial production. The company also focuses on innovation, holding 8 granted patents (1 in India and 7 internationally), along with 24 pending patent applications worldwide. The company’s workforce, as of September 2024, consists of 600 professionals, including skilled chemists, biologists, and engineers with expertise across various scientific and technical fields.
Strengths
- End-to-end CRDMO capabilities across small and large molecules with integrated services from discovery to commercial manufacturing, making it the fastest-growing Indian CRDMO with presence in all three segments.
- Focused business model targets emerging pharma and biotech firms needing external expertise, regulatory support, and scalable manufacturing.
- Scalable and compliant manufacturing infrastructure with two cGMP facilities and 142 kL capacity (expanding to 182 kL), backed by major capital investments.
Risk factors
- Regulatory compliance and inspection delays by authorities like USFDA and PMDA may disrupt manufacturing and impact revenue due to approval or compliance issues.
- Heavy reliance on manufacturing units (Unit I, II, and upcoming Unit III) exposes the company to risks from delays, labor shortages, or material issues affecting CRDMO and specialty ingredient operations.
- Exposure to hazardous materials increases operational risks despite safety upgrades, with potential for accidents, operational disruption, or damage to people and property.
Promoters
Ajay Bhardwaj
Ganesh Sambasivam
K Ravindra Chandrappa
Ishaan Bhardwaj
Registrar & documents
Lead manager
Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Jm Financial Limited, Nomura Financial Advisory And Securities (India) Private Limited , Securities (India) Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099
+91 080 6672 400
[email protected]Company website ↗Understanding ANTHEM IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.